122 Grants (Page 2 of 5)
2006
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE TRIAL OF A NOVEL CCR5 AN
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-34-5250), $9,502USD, 12/01/2005 -- 11/30/2006
 
ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS PRESENTING WITH ACUTE
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-34-5199), $21,199USD, 12/01/2005 -- 11/30/2006
 
A PHASE IIIB, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF THE SAFETY AND EFF
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-34-5234), $6,579USD, 12/01/2005 -- 11/30/2006
 
A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RI
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-34-5272), $9,502USD, 12/01/2005 -- 11/30/2006
 
EFFECT OF IMMUNIZATION WITH THE MRK AD5 HIV-1 GAG VACCINE IN HIV INFECTED
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-34-5227), $22,659USD, 12/01/2005 -- 11/30/2006
 
Endothelial Dysfunction Due to HIV-1 Protease Inhibitors
Goldman, Mitchell
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 5R01HL072711-05), $266,876USD, 09/30/2002 -- 07/31/2009
 
IMPACT OF THERAPEUTIC DRUG MONITORING ON VIROLOGIC RESPONSE TO A SALVAGE REGIMEN
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-34-5192), $28,508USD, 12/01/2005 -- 11/30/2006
 
PHASE IB/IIA DOSE-FINDING SAFETY AND ACTIVITY STUDY OF AMD11070 (AN ORALLY
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-34-5239), $48,244USD, 12/01/2005 -- 11/30/2006
 
PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY OF THE SAFETY AND EFFICACY OF SCH 41
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-34-5232), $6,579USD, 12/01/2005 -- 11/30/2006
 
PREDICTORS OF IMMUNOLOGIC AND CLINICAL PROGRESSION IN SUBJECTS WITH CD4+ CELL
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-34-5186), $730USD, 12/01/2005 -- 11/30/2006
 
SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACOKINETICS AMONG HIV-1-INFECTED
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-34-5258), $8,772USD, 12/01/2005 -- 11/30/2006
2005
ADULT AIDS CLINICAL TRIALS UNIT
Goldman, Mitchell
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 3U01AI025859-18S1), $1,881,400USD, 01/01/2000 -- 12/31/2008
 
ADULT AIDS CLIN TRIAL GRP LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) - A5001
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 2M01RR000750-33-0762), $210,513USD, 07/12/2005 -- 11/30/2005
 
ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS PRESENTING WITH ACUTE
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 2M01RR000750-33-0822), $15,889USD, 07/12/2005 -- 11/30/2005
 
A PHASE II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 2M01RR000750-33-0876), $3,177USD, 07/12/2005 -- 11/30/2005
 
A PHASE IIIB, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF THE SAFETY AND EFF
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 2M01RR000750-33-0882), $794USD, 07/12/2005 -- 11/30/2005
 
IMPACT OF THERAPEUTIC DRUG MONITORING ON VIROLOGIC RESPONSE TO A SALVAGE REGIMEN
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 2M01RR000750-33-0816), $30,981USD, 07/12/2005 -- 11/30/2005
 
PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY OF THE SAFETY AND EFFICACY OF SCH 41
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 2M01RR000750-33-0880), $10,326USD, 07/12/2005 -- 11/30/2005
 
PREDICTORS OF IMMUNOLOGIC AND CLINICAL PROGRESSION IN SUBJECTS WITH CD4+ CELL
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 2M01RR000750-33-0810), $4,766USD, 07/12/2005 -- 11/30/2005
2004
ADULT AIDS CLINICAL TRIALS UNIT
Goldman, Mitchell
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5U01AI025859-18), $1,790,506USD, 01/01/2000 -- 12/31/2008
 
Adult Aids clin. trial grp longitudinal linked randomized trials (ALLRT) - A5001
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-32-0762), $186,562USD, 12/01/2003 -- 11/30/2004
 
ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS PRESENTING WITH ACUTE
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-32-0822), $11,660USD, 12/01/2003 -- 11/30/2004
 
IMPACT OF THERAPEUTIC DRUG MONITORING ON VIROLOGIC RESPONSE TO A SALVAGE REGIMEN
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-32-0816), $30,316USD, 12/01/2003 -- 11/30/2004
 
PREDICTORS OF IMMUNOLOGIC AND CLINICAL PROGRESSION IN SUBJECTS WITH CD4+ CELL
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-32-0810), $10,105USD, 12/01/2003 -- 11/30/2004
2003
ADULT AIDS CLINICAL TRIALS UNIT
Goldman, Mitchell
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5U01AI025859-17), $2,028,458USD, 01/01/2000 -- 12/31/2004